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UrineAbstract Two rapid, simple, sensitive and selective spectrophotometric methods have been devel-
oped for the quantitative estimation of nifedipine in pharmaceutical formulations and different
human body ﬂuids (serum and urine). The proposed methods are based on the reduction of the
nitro group to amino group of the drug. The resulting amine was then subjected to proposed meth-
ods. Method A is based on the oxidation followed by coupling of nifedipine with 3- methyl-2-ben-
zothiazolinone hydrazone (MBTH) in presence of ferric chloride (FeCl3) to form green colored
chromogen at 685 nm. Method B is based on the formation of oxidative coupling reaction between
the corresponding drug and brucine – NaIO4 to form violet colored chromogen at 546 nm. The pro-
cedures described were applied successfully to the determination of the compound in their dosage
forms and body ﬂuids. The results showed that the proposed procedures compared favorably with
reference method are satisfactory sensitive, accurate and precise. The optical characteristics such as
Beer’s law limits, molar absorptivity, Sandell’s sensitivity and various statistical data are reported.
The results of the analysis for the two methods have been validated statistically and by recovery
studies.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Nifedipine is chemically known as dimethyl-1,4-dihydro-2,6-
dimethyl-4-(2-nitrophenyl) pyridine-3,5 dicarboxylate.(Fig. 1 A) It is pharmacologically a selective L-type calcium
channel antagonist (Matrindale the Extra Pharmacopoeia,
2002). It causes coronary vasodilation and increases coronary
blood ﬂow. It reduces the total peripheral vascular resistance,
for which it is widely used in the treatment of hypertension
angina pectoris, various other cardiovascular disorders and
Reynaud’s phenomenon (Sorkin et al., 1985; Kahan et al.,
1981; Hardman et al., 1996). It is mainly used in the treat-
ment of diuretics and ACE (Tripathi K.D.) inhibitors
although calcium channels antagonists are still favored as pri-
mary treatment for older black patients – sub lingual. Nifed-
ipine has previously been used in hypertensive emergencies. It
Figure 1 Chemical structures of (A) Nifedipine (B) Nitro phenyl
pyridine.
S1604 P. Tulasamma, P. Venkateswarluhas a very low bioavailability, and it is photosensitive and
thermally unstable. This compound, when exposed to day-
light and certain wavelengths or artiﬁcial light readily con-
verts to a nitro phenyl pyridine derivative (NFPD)
(Fig. 1B) (Henry, 1980; Miller, 1987; Stone et al., 1980).
Blood pressure diabetes and LDL cholesterol are casual risk
factors for cardiovascular diseases (CVD) and their combined
effects make this disease common. A pill containing different
active ingredients (Polly Pill) to overcome these factors is
more beneﬁcial than the common pills with only one, interns
of cost and patient compliance. Nifedipine is a common pre-
scribed active ingredient for CVD. Nifedipine, a highly non
polar compound, is absorbed completely from the gastroin-
testinal tract, predominately from the Jejunum, but has a
very low bioavailability mainly due to presystemic metabo-
lism. Following absorption, nifedipine is further metabolized
in the small intestine and liver to more polar compounds
which are primarily eliminated by the kidney (Dokladaiova
et al., 1982; Schellens et al., 1991; Kleinbloesem et al.,
1984). Nifedipine is a photolabile compound, undergoing oxi-
dative biotransformation in human body into pharmacologi-
cally inactive metabolites (Dokladaiova et al., 1982; Suzuki
et al., 1985; Ohkubo et al., 1992).
The literature has reported some methods for nifedipine
determination in biological ﬂuids, which included gas chroma-
tography, high performance liquid chromatography with
either UV detection or electrochemical detection, ﬂuorescence
procedures, ﬁrst derivative spectroscopy, Voltammetric meth-
od and LC–MS combining a simple liquid–liquid extraction
(Kondo et al., 1980; Sheridan et al., 1989; Jankowski et al.,
1994; Suzuki et al., 1985; Ozattin et al., 2002). Additionally,
the methods reported to quantify nifedipine in bulk and in
pharmaceuticals formulation involved a variety of analytical
techniques such as high performance thin layer chromato-
graphic, liquid chromatographic, gas chromatographic, polar-
ographic, micellar electro kinetic chromatography, electro
analytical and spectrophotometric methods (Patravale et al.,
2000; Rahman et al., 2004; Rahman and Hoda, 2002; Karadi
et al., 2000; Tu et al., 1995; Dumitrescu et al., 2001; Richter
et al.,1997; Beaulieu et al., 1991; Kalieswari et al., 2002; Kas-
ture and Ramteke, 2005; Milenovic et al., 2008; Rodrı´guez
et al., 2008; Hemmateenejad et al., 2009).
Surprisingly, according to the best of our knowledge few
spectrophotometric methods for the determination of nifedi-
pine in pharmaceutical formulations, body ﬂuids and other
additives were reported. The present study documents an accu-rate, sensitive, rapid, selective and reproducible visible spectro-
photometric assay which meets an accepted analytical
validation. Spectrophotometry is the technique of choice even
today in the laboratories of research, hospitals and pharma-
ceutical industries due to its low cost and inherent simplicity.2. Experimental
2.1. Apparatus
Shimadzu UV–visible double beam spectrophotometer (model
2450) with 1 cm matched quartz cells was used for all the spec-
tral measurements.
2.2. Materials and reagents
All chemicals and reagents were of analytical grade and water
was always double distilled water.
(1) Nifedipine was kindly supplied by Novartis Pharmaceu-
ticals Ltd. Mumbai, India its Purity was found to be
100.024 ± 0.84.
(2) Brucine solution (Loba, 0.2%; 5.067 · 10–3 M): pre-
pared by dissolving 200 mg of Brucine in 100 ml distilled
water.
(3) NaIO4 solution (BDH, 0.2%; 9.35 · 10–3 M):
prepared by dissolving 200 mg of sodium metaperio-
date in 100 ml distilled water and standardized
iodometrically.
(4) H2SO4 solution (Qualigens, 2.3 M): Prepared by diluting
6.38 ml of 18 M H2SO4 to 100 ml with distilled water.
(5) MBTH (Merck, 0.2%): Prepared by dissolving 200 mg
in 100 ml distilled water.
(6) FeCl3 (Merck, 0.5%): Prepared by dissolving 500 mg in
100 ml distilled water.
(7) Pharmaceutical formulations: Nicardia retard – 10 mg
nifedipine per tablet (Local market Tirupati).
Calciguard – 10 mg and Adalat retard – 10 mg nifedipine
per tablet (Novartis Pharmaceuticals Ltd., Mumbai, India).
2.3. Reduction of nitro group in Nifedipine (Olajire Aremu and
Ofﬁong Edet, 2009; Tulasamma and Venkateswarlu, 2009)
100 mg of nifedipine pure or equivalent tablet powder was
accurately weighed and dissolved in 20 ml of methanol. This
solution was treated with 10 ml of 5 N HCl and 0.5 g of Zinc
powder was added in the portions, while shaking and reﬂuxed
at 80 C for 10 min. The solution was ﬁltered using a Whatt-
man ﬁlter paper 41 to remove the insoluble matter and the vol-
ume was made up to 100 ml with methanol to get the
concentration 1 mg/ml.
2.4. Preparation working standard solution
The resulting amine from the above solution 10 ml was taken
into 100 ml volumetric ﬂask and made up to the mark with
methanol to get the concentration 100 lg ml1 and dilution
was carried out to the further working standards.
y = 0.0577x + 0.0012
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Figure 3 Calibration plot of Nifedipine (Method B).
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Figure 4 Absorption spectrum of (A) blank (B) MBTH with
Nifedipine.
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2.5.1. Method A
Aliquots of nifedipine ranging from 1–19 lg ml1 were trans-
ferred into a series of 10 ml volumetric ﬂasks. To each ﬂask
1 ml of aqueous solution of ferric chloride (0.5% w/v),
1.0 ml aqueous solution of MBTH (0.2% w/v) were added fol-
lowed by dil HCl. The ﬁnal volume was made up to 10 ml with
distilled water. The absorbance of the green colored species
formed was measured at 685 nm against reagent blank and
beer’s law was obeyed in concentration range of 1–19 lg ml1.
The amount of nifedipine present in the sample was computed
from calibration curve (Fig. 2).
2.5.2. Method B
Aliquots of nifedipine solution 4–18 lg ml1 were transferred
into 10 ml volumetric ﬂasks. To, this 3 ml of Brucine solution
1.5 ml sodium meta periodate solution and 2 ml of (1.2 M) sul-
phuric acid were added to each ﬂask. The ﬂasks were shaken
thoroughly and placed in a boiling water bath for about
15 min. The reaction mixture was then cooled to room temper-
ature and total volume was adjusted to 10 ml with distilled
water. The absorbance of each solution was measured at
546 nm against a reagent blank. The amount of nifedipine
present in the sample was computed from calibration curve
(Fig. 3).
3. Results and discussion
3.1. Method A
3.1.1. Absorption spectra (David et al., 2009)
The formation of green colored complex was employed in the
quantitative detection of nifedipine with MBTH in presence of
ferric chloride. However when MBTH was initially mixed with
nifedipine and then with oxidizing agent, a green colored com-
pound was produced with maximum absorbance in the visible
range at 685 nm and shown in Fig. 4. MBTH loses two elec-
trons and one proton due to oxidation with Fe (II), forming
an electrophilic intermediate, which is the active coupling spe-
cies. The electrophilic intermediate and the analyte under goes
electrophilic reaction with the formation of colored product
and the elimination of one molecule of water.y = 0.0831x + 0.0009
R2 = 0.9973
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Figure 2 Calibration plot of Nifedipine (Method A).3.1.2. Optimum reaction conditions for complex formation
The optimizations of the methods were carefully studied to
achieve complete reaction formation, highest sensitivity and
a maximum absorbance. Reaction conditions of oxidative cou-
pling complex were found by studying with preliminary
experiments.
3.1.3. Effect of reagent
The addition of 1.0 ml of Fe3+-MBTH solution was sufﬁcient
to obtain the maximum and reproducible absorbance for
6.0 lg ml1 nifedipine. Smaller amounts resulted in complete
complex formation. Increased concentration had no effect on
complex formation, although absorbance increased slightly
owing to the reagent background used.
3.1.4. Effect of reaction time and stability of colored species
The optimum reaction time was investigated from 0.5 to
4.0 min by following the color development at ambient tem-
perature (25 ± 2 C). Complete color intensity was attained
after 2.0 min of mixing for complex. Rising the temperature
up to 30 C has no effect on the absorbance of the formed
complex, where as above 30 C, the absorbance start to decay.
The absorbance remains stable for at least 3 h.
Table 2 Tolerance of different species in the determination of
Nifedipine.
Species added Maximum tolerable mole ratio
Lactose, glucose, sugar 200
20
Starch, talc 200
20
Sodium chloride, titanium dioxide 200
20
Magnesium sterate 200
20
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Figure 5 Absorption spectrum of (A) blank (B) brucine with
Nifedipin.
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The reaction product, green color was found to ﬂocculate with
in 20–30 min of color development. To delay the ﬂocculation,
acid was added before dilution. Hydrochloric acid was found
to give more stable color and reproducible results.
3.1.6. Effect of order in which reagents were added
After ﬁxing all other parameters, a few of the experiments were
performed to ascertain the inﬂuence of the order in which re-
agents were added. The following order: Drug-reagent -acid
gave maximum absorbance and stability.
3.1.7. Effects of interference
In pharmaceutical analysis, it is important to test the selectivity
towards the excipients and ﬁllers added to the pharmaceutical
preparations. Several species which can occur in the real sam-
ples together with drug were investigated. The level of interfer-
ence was considered acceptable. Commonly encountered
excipients such as talc, starch, glucose etc. did not interfere
in the determination.
In order to apply the proposed method to the analysis of
pharmaceutical formulations, the inﬂuence of commonly used
excipients starch, lactose, glucose, sugar,talc, sodium chloride,
titanium dioxide and magnesium sterate and additives was
studied by preparing solutions containing 2.0 · 103 M Nif-
edepine and increasing concentration of the potential interfer-
ence up to 1.0 · 103 M. The tolerance (Table 2) of each
foreign compound was taken as the largest amount yielding
an error of less than ±2% in the analytical signal of
nifedipine.
3.2. Method B
3.2.1. Absorption spectra (Murali et al., 1984)
Brucine (2,3-dimethoxystrychnidin – 10 one) under acidic con-
ditions has been reported to be an effective reagent for the
spectrophotometric determination of NO3 , NO

2 and Ce
4+.
Sodium periodate (IO4 ) is an efﬁcient oxidant and is also color
stabilizer. This investigation was concerned with the develop-
ment of a spectrophotometric method for the routine determi-
nation of nifedipine using brucine – IO4 . The violet color kmax
of 546 nm (Fig. 5) developed was stable for 10 h and hence was
suitable for routine work with good precision and accuracy.Table 1 Optical and regression characteristics of the proposed
methods.
Parameteras Method A Method B
kmax (nm) 685 546
Beer’s law limit (lg ml1) 1–19 4–18
Molar absorptivity (L mol1 cm1) 2.77 · 104 1.59 · 104
Sandell’s sensitivity (lg cm2/0.001 A.U) 0.13 0.20
Regression equation (Y= mX+ C)
Slope (m) 0.0831 0.0577
Intercept (C) 0.0009 0.0012
Correlation coeﬃcient (r2) 0.9973 0.9988
% Relative Standard deviation 0.42 0.19
Color Green Violet
LOD (lg ml1) 0.21 0.23
LOQ (lg ml1) 0.70 0.533.2.2. Optimum reaction conditions
The optimum conditions for the method was established by
varying one parameter at a time and keeping the others ﬁxed
and observing the effect produced on the absorbance of col-
ored species and incorporated in the procedure.
3.2.3. Effect of reagent concentration
The effect of reagent was studied by measuring the absorbance
of solution containing a ﬁxed concentration of nifedipine
(10 lg ml1) and varied amount of the respective reagent.
Maximum color intensity of the complex was achieved with
3 ml and 1.5 ml of 0.2% w/v Brucine and NaIO4 reagent solu-
tions respectively for nifedipine. Although a larger volume of
the reagent had no pronounced effect on the absorbance of
the formed complex.
3.2.4. Effect of time and temperature
The reaction of nifedipine depends on time, maximum absor-
bance intensity was observed after 8.0 min for nifedipine at
room temperature. The reaction of nifedipine was studied at
different temperatures (25–100 C) the values of maximum
absorbance of the oxidative coupling product was almost con-
stant at 25–80 C for nifedipine, further temperature decreases
the absorbance.
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The optimum sulphuric acid strength of the 25 ml of diluted
reaction mixture for maximum color development with mini-
mum blank color was 0.1–0.15 M.
3.2.6. Sequence of reagents were added
The following order gives the maximum absorbance and stabil-
ity i.e. Drug-reagent -acid.
3.3. Method validation
3.3.1. Linearity
Under the optimum conditions described, Beer’s law holds
over the concentration ranges 1–19 and 4–18 lg ml1 respec-
tively for Methods A and B, calibrations were constructed
by plotting absorbance versus concentrations. We calculated
the apparent molarabsorptivity, Sandell’s sensitivity, relative
standard deviation and the regression equations (Table 1).
3.3.2. Sensitivity
The detection limit LOD for the proposed methods were calcu-
lated using the following equations (Miller and Miller, 1993)
LOD ¼ 3S=K
where S is the standard deviation of replicate determination
values under the same conditions as for the sample analysis
in the absence of analyte and K is the sensitivity, namely the
slope of the calibration graph. In accordance with the formula,
the detection limits were found to be 0.21 and 0.23 lg/ml for
MBTH, brucine respectively.
The limits of Quantitations, LOQ deﬁned as (Miller and
Miller, 1993):
LOQ ¼ 10S=k
According to this equation, the limits of quantitation were
found to be 0.70 and 0.53 lg/ml for MBTH, Brucine
respectively.
3.3.3. Accuracy and precision (Ayman and Hassan, 2008)
In order to determine the accuracy and precision of the pro-
posed methods, solutions containing four different concentra-
tion of nifedipine were prepared and analyzed in six replicates.
The relative standard deviation as precision and percentage
relative error (Err%) as accuracy of the suggested methods
were calculated at 95% conﬁdence levels, and can be consid-
ered satisfactory. Precision was carried out by six determina-
tions at four different concentrations in these
spectrophotometric methods. The percentage relative error
was calculated according to the following equation.Table 3 The Intra day and inter day precision and accuracy data t
Method Nifedipine taken (lg ml) Intra-day
Found (lg/ml) Recoverya ± R
A 1 1.002 100.20 ± 1.09
3 3.002 100.06 ± 0.36
B 4 3.990 99.79 ± 0.32
8 8.001 100.01 ± 0.14
a Average of ﬁve determinations.Err% ¼ ½ðFoundAddedÞ=Added  100
The inter-day and intra-day precision and accuracy results
are shown in (Table 3). The analytical results for accuracy
and precision show that the methods proposed have good
repeatability and reproducibility.3.3.4. Robustness and ruggedness
For the evaluation of the method robustness, some parameters
were interchanged, reagent concentration, wavelength range
and shaking time. The capacity remains unaffected by small
deliberate variations. Method ruggedness was expressed as
R.S.D% of the same procedure applied by two analysts and
in two different instruments of different days. The results
showed no statistical difference between different analysts
and instruments suggesting that the developed methods were
robust and rugged.3.3.5. Reference method
An accurately weighed amount of tablet powder equivalent to
100 mg of nifedipine was transferred into 100 ml volumetric
ﬂasks. To this 75 ml of methanol was added and shaken well
for about 15 min. The contents were diluted with methanol
up to the mark and mixed thoroughly. The solution was ﬁl-
tered, then 2 ml of ﬁltrate was pipette out into a 100 ml volu-
metric ﬂask and made up to the mark with methanol for
obtaining a concentration of 20 lg ml1. Into a series of 5 ml
graduated tubes, aliquots of drug solution ranging from 0.5–
0.3 lg ml1were taken and diluted to mark with methanol.
Read the absorbance at 266 nm against a solvent blank. The
drug was read from its calibration graph.3.4. Applications
3.4.1. Analysis of pharmaceutical preparations
The proposed methods have been successfully applied to the
determination of nifedipine in commercial tablet. The results
obtained are shown in Table 4. The two suggested methods
were applied successfully to the determination of nifedipine
in commercial tablet. Six replicate determinations were ob-
tained and the assay results were in a good agreement with per-
centage recovery. Moreover, to check the validity of the
proposed methods, dosage forms were tested for possible inter-
ference with standard addition method. There was no signiﬁ-
cant difference between slopes of calibration curves and
standard addition methods at two methods. To evaluate the
validity and reproducibility of the method, known amounts
of pure drug were added to previously analyze pharmaceuticalo nifedipine obtained by the proposed methods.
Inter-day
SD% RE% Found lg ml1 Recoverya ± RSD% RE%
0.20 1.003 100.30 ± 1.20 0.30
0.06 3.003 100.06 ± 0.32 0.10
0.20 3.999 99.99 ± 0.37 0.01
0.01 8.002 100.02 ± 0.16 0.02
Table 4 Assay of nifedipine in pharmaceutical formulations.
Formulation Amount taken (lg ml1) Amount found (lg ml1) % Recoverya ± RSD Reference methodb
Method A Method B Method A Method B
Calciguard – 10 mg 3 3.033 3.003 101.10 ± 0.67 100.10 ± 0.32
9 9.023 9.012 100.25 ± 0.42 100.13 ± 0.27 103.00
Naciarda retard – 10 mg 4 4.018 4.017 100.45 ± 1.05 100.42 ± 0.92
8 8.014 8.012 100.17 ± 0.41 100.17 ± 0.22
a Average of ﬁve determinations.
b Hemmateenejad et al. (2009).
Table 5 The recovery of nifedipine in urine and serum.
Sample Added lg ml1 Amount found lg ml1 % Recoverya ± RSD
Method A Method B Method A Method B
Serum (2.5%) 4 4.00 4.001 100.0 ± 0.39 100.01 ± 0.70
8 8.00 8.002 100.0 ± 0.11 100.03 ± 0.13
Urine (5%) 4 4.00 4.003 100.01 ± 0.39 100.09 ± 0.23
8 8.002 8.002 100.02 ± 0.09 100.03 ± 0.12
a Average of ﬁve determinations.
S1608 P. Tulasamma, P. Venkateswarlupreparations and the mixtures were analyzed by the proposed
methods. The percent recoveries are also given in Table 4.
3.4.2. Analysis of recovery of nifedipine from serum and urine
samples
This proposed method was also applied to the determinations
of nifedipine in serum and urine samples.
The serum and urine samples were prepared for the anal-
ysis of recovery of nifedipine with these proposed methods.
The serum and urine samples were obtained from healthy
volunteers. The urine samples were centrifuged for 15 min
at 3000 r/min to remove the suspended matter before deter-
mination. The serum and urine samples were added respec-
tively according to the proposed procedure. The results are
presented in Table 5. High accuracy and good recoveries
are obtained, which indicates that the proposed methods
can be successfully applied to recover nifedipine in the serum
and urine samples.
4. Conclusions
The reagents utilized in the proposed methods are cheaper,
readily available and the proposed method does not involve
any critical reaction conditions or tedious sample preparation
and extraction procedure. The method is unaffected by slight
variations in the experimental conditions, such as reagent con-
centration or temperature. The proposed methods are sufﬁ-
ciently sensitive to permit determinations even down to
12 lg ml1. The sensitivity in terms of linearity, molarabsorp-
tivity, precession and RSD of the methods are very suitable for
the determination nifedipine in tablets and body ﬂuids (serum
and urine). Moreover the methods are free from interference
by common additives and excipients. The comparative study
of the molarabsorptivity indicated good sensitivity of the pro-
posed methods which follow the order of MBTH> brucine–NaIO4. These advantages encourage the application of the
proposed methods in routine quality control analysis of nifed-
ipine in pharmaceutical and body ﬂuids (serum and urine).
The proposed methods were compared with reported meth-
ods (Rahman and Najmul Hejaz Azmi, 2005); in this study the
method B is based on the formation of molybdenum blue com-
plex by reduction of ammonium molybdate with drug. The
concentration of nifedipine was determined at 803 nm and lin-
earity range 2.5–45.0 lg ml1 by spectrophotometric method.
In this manuscript, the developed methods have small linearity
range 1–19 and 4–18 lg ml1 and wavelength of 685 nm and
546 nm. The statistical analyses show that the data from pro-
posed methods are in good agreement with those of reported
methods.
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